Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

Table 3

Efficacy rates and duration of response associated with different chemotherapy regimens for ASTS.

	Probability of achieving:				Median duration of response (months) in:
	Complete remission	Partial remission	Stable disease	Progressive disease	Complete remission	Partial remission	Stable disease
First-line treatments
Doxorubicin/ifosfamide	0.06	0.21	0.38	0.35	15.44	7.69	6.41
	[16, 17, 22–32]	[16, 17, 22–32]	[16, 17, 22–32]	[16, 17, 22–32]	[16, 17, 22, 24, 27, 28, 31, 33]	[16, 17, 22, 24, 27, 28, 31, 33]	[16, 17, 22, 24, 27, 28, 31, 33]
Trabectedin	0.03	0.11	0.14	0.72	17.74	8.75	7.48
	[34]	[34]	[34]	[34]	[34]	[34]	[34]
Second-line treatments
CYVADIC^*∧	0.03	0.19	0.39	0.39	12.13	6.57	5.75
Docetaxel	0.00	0.11	0.25	0.64	0.00	6.60	7.17
	[35–37]	[35–37]	[35–37]	[35–37]	[35, 36]	[35, 36]	[35, 36]
Doxorubicin	0.02	0.07	0.31	0.61	12.13*	6.57*	5.75*
	[38, 39]	[38, 39]	[38, 39]	[38, 39]
Doxorubicin/ifosfamide	0.05	0.27	0.37	0.31	12.13*	6.57*	5.75*
	[22, 38]	[22, 38]	[22, 38]	[22, 38]
Gemcitabine	0.00	0.08	0.33	0.59	0.00	4.46	3.86
	[40–45]	[40–45]	[40–45]	[40–45]	[43, 46, 47]	[43, 46, 47]	[43, 46, 47]
Gemcitabine/dacarbazine	0.01	0.10	0.39	0.51	10.48	6.50	5.79
	[48–50]	[48–50]	[48–50]	[48–50]	[48]	[48]	[48]
Gemcitabine/docetaxel	0.05	0.19	0.41	0.35	12.13*	6.57*	5.75*
	[40, 51–54]	[40, 51–54]	[40, 51–54]	[40, 51–54]
Gemcitabine/paclitaxel*	0.03	0.19	0.39	0.39	12.13	6.57	5.75
Gemcitabine/vinorelbine	0.02	0.10	0.10	0.78	16.10	16.10	9.60
	[55, 56]	[55, 56]	[55, 56]	[55, 56]	[56]	[56]	[56]
Ifosfamide	0.02	0.13	0.24	0.61	13.77	8.75	7.61
	[38, 57–60]	[38, 57–60]	[38, 57–60]	[38, 57–60]	[58, 60]	[58, 60]	[58, 60]
Ifosfamide/epirubicin*	0.05	0.27	0.37	0.31	12.13	6.57	5.75
Liposomal doxorubicin*	0.02	0.07	0.31	0.61	12.13	6.57	5.75
Trabectedin	<0.01	0.07	0.44	0.49	16.14	10.25	8.91
	[19, 34, 61–67]	[19, 34, 61–67]	[19, 34, 61–67]	[19, 34, 61–67]	[19, 34, 61, 63–65]	[19, 34, 61, 63–65]	[19, 34, 61, 63–65]
Trofosfamide	0.00	0.03	0.19	0.79	12.13*	6.57*	5.75*
	[68–70]	[68–70]	[68–70]	[68–70]
Trofosfamide/etoposide*	0.03	0.19	0.39	0.39	12.13	6.57	5.75

 *Values were estimated. ^∧CYVADIC: cyclophosphamide, vincristine, adriamycin and dacarbazine.